- Home
- NBTX vs SANG Comparison
NBTX vs SANG Comparison
Compare NBTX & SANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- SANG
- Stock Information
- Founded
- NBTX 2003
- SANG 1984
- Country
- NBTX France
- SANG Canada
- Employees
- NBTX N/A
- SANG N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- SANG Computer Software: Programming Data Processing
- Sector
- NBTX Health Care
- SANG Technology
- Exchange
- NBTX Nasdaq
- SANG Nasdaq
- Market Cap
- NBTX 178.7M
- SANG 158.2M
- IPO Year
- NBTX 2020
- SANG 2021
- Fundamental
- Price
- NBTX $3.61
- SANG $4.36
- Analyst Decision
- NBTX Strong Buy
- SANG
- Analyst Count
- NBTX 1
- SANG 0
- Target Price
- NBTX $12.00
- SANG N/A
- AVG Volume (30 Days)
- NBTX 13.1K
- SANG 10.8K
- Earning Date
- NBTX 04-23-2025
- SANG 05-07-2025
- Dividend Yield
- NBTX N/A
- SANG N/A
- EPS Growth
- NBTX N/A
- SANG N/A
- EPS
- NBTX N/A
- SANG N/A
- Revenue
- NBTX $45,220,186.00
- SANG $241,243,000.00
- Revenue This Year
- NBTX N/A
- SANG N/A
- Revenue Next Year
- NBTX N/A
- SANG $3.21
- P/E Ratio
- NBTX N/A
- SANG N/A
- Revenue Growth
- NBTX 526.17
- SANG N/A
- 52 Week Low
- NBTX $2.76
- SANG $4.04
- 52 Week High
- NBTX $7.51
- SANG $7.99
- Technical
- Relative Strength Index (RSI)
- NBTX 52.08
- SANG 29.21
- Support Level
- NBTX $3.32
- SANG $4.42
- Resistance Level
- NBTX $3.77
- SANG $4.85
- Average True Range (ATR)
- NBTX 0.21
- SANG 0.18
- MACD
- NBTX 0.01
- SANG 0.04
- Stochastic Oscillator
- NBTX 60.55
- SANG 22.22
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.